Get the latest tech news
U.S. lawmakers are trying to bar Chinese biotech companies over fears about America’s failure to compete with China in the industry
Bills have been introduced in the House and Senate to bar “foreign adversary biotech companies of concern” from doing business with federally funded medical providers.
The debate over biotechnology is taking place as the Biden administration tries to stabilize the volatile U.S.-China relationship, which has been battered by a range of issues, including a trade war, the COVID-19 pandemic, cybersecurity and militarization in the South China Sea. “Both the Chinese government and the Americans have identified biotech as an area important for investment, a sector that presents an opportunity to grow their economy,” said Tom Bollyky, the Bloomberg chair in global health at the Council on Foreign Relations. Puglisi described BGI, a major Chinese biotech company identified in both the House and Senate bills, as “a national champion” that is subsidized and given favored treatment by the state in a system that “blurs private and public as well as civilian and military.”
Or read this on r/technology
